SCHEMBL6789329

SCHEMBL6789329

CC(C)NC(=O)C1(CCCCN2CCN(c3ccc(-c4ccccc4)cc3)CC2)c2ccccc2-c2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 7/20 0.44
HTR7 P34969 5/20 0.44
DRD2 P14416 5/20 0.44
HTR6 P50406 2/20 0.44
HTR2A P28223 2/20 0.42
HTR2C P28335 2/20 0.42
HTR2B P41595 2/20 0.42
DRD4 P21917 2/20 0.42
DRD3 P35462 2/20 0.41
CHRM2 P08172 1/20 0.41
ADRA2A P08913 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CHRM1 P11229 1/20 0.41
DRD1 P21728 1/20 0.41
TBXA2R P21731 1/20 0.41
PTGS1 P23219 1/20 0.41
SLC6A2 P23975 1/20 0.41
ADRA1A P35348 1/20 0.41
OPRM1 P35372 1/20 0.41
MTTP P55157 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6789349 0.89 HTR7 (0.45) HTR1AHTR7DRD2HTR2AHTR2C
SCHEMBL6792842 0.87 DRD3 (0.46) HTR7DRD2HTR2AHTR2CHTR2B
SCHEMBL6791987 0.86 GAA (0.47) HTR1ADRD2DRD3
SCHEMBL6790988 0.86 DRD3 (0.46) HTR7DRD2HTR2AHTR2CHTR2B
SCHEMBL6797449 0.85 HTR2A (0.52) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL6800314 0.83 HTR1A (0.46) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL6793341 0.83 HTR1A (0.46) HTR1AHTR7DRD2HTR2ADRD4
SCHEMBL6792470 0.83 HTR7 (0.45) HTR1AHTR7DRD2DRD4DRD3
SCHEMBL6792149 0.83 MTTP (0.59) DRD3CHRM2ADRA2AADORA3CHRM1
SCHEMBL6790535 0.83 HTR1A (0.50) HTR1AHTR7DRD2HTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818644-B1 FLUORENE-9-CARBOXYLIC AMIDES; INHIBITORS OF MICROSOMAL TRIGLYSERIDE-TRANSFER PROTEIN (MTP); ANTILIPEMIC AGENTS; ATHEROSCLEROSIS, DIABETES, EATING DISORDERS, AND PANCREATITIS BOEHRINGER INGELHEIM PHARM GMBH & CO, KG (DE) 2004-11-16 US disclosed